Aspire Biopharma (ASBP) investors back all Special Meeting proposals

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on June 16, 2026, where stockholders constituting a quorum voted on several matters. The filing shows that each proposal received strong support, with the first proposal receiving 1,742,683 votes for, 107,523 against, and 4,818 abstentions, and no broker non-votes. Two additional proposals also passed with similar levels of support, including one with 1,745,709 votes for and another with 1,739,702 votes for, and no broker non-votes in any case. The company remains listed on The Nasdaq Stock Market LLC under the symbols ASBP for its common stock and ASBPW for its warrants.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Proposal 1 votes for: 1,742,683 votes Proposal 1 votes against: 107,523 votes Proposal 1 abstentions: 4,818 votes +4 more

7 metrics

Proposal 1 votes for 1,742,683 votes Special Meeting of Stockholders on June 16, 2026

Proposal 1 votes against 107,523 votes Special Meeting of Stockholders on June 16, 2026

Proposal 1 abstentions 4,818 votes Special Meeting of Stockholders on June 16, 2026

Proposal 2 votes for 1,745,709 votes Special Meeting of Stockholders on June 16, 2026

Proposal 3 votes for 1,739,702 votes Special Meeting of Stockholders on June 16, 2026

Broker non-votes each proposal 0 votes All three proposals, June 16, 2026 meeting

Par value per share $0.0001 per share Common stock

Key Terms

Special Meeting of Stockholders, Broker Non-Votes, Emerging growth company, Common Stock, par value $0.0001 per share, +1 more

5 terms

Special Meeting of Stockholders regulatory

"On June 16, 2026, at the Special Meeting of Stockholders (the “Meeting”)"

A special meeting of stockholders is an unscheduled gathering called to let shareholders vote on specific, often urgent company decisions—like mergers, major asset sales, changes to the board, or amendments to governing rules. Think of it as an emergency town hall where owners cast ballots in person or by mail/online; outcomes can materially change a company’s strategy, control or value, so investors pay close attention and may need to vote or adjust holdings accordingly.

Broker Non-Votes regulatory

"Votes For | Votes Against | Votes Abstain | Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 06/22/2026 - 04:36 PM Accepted by SEC EDGAR 06/22/2026 - 04:35 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

ASPIRE BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41293

33-3467744

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

23150 Fashion Drive, Suite 230

Estero, Florida

33928

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (908) 987-3002

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ASBP	The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of common stock	ASBPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 16, 2026, at the Special Meeting of Stockholders (the “Meeting”) of Aspire Biopharma Holdings, Inc. (the “Company”), the Company’s stockholders constituting a quorum voted on, and approved, the matters described below.

To authorize, pursuant to that certain Warrant to Purchase Common Stock Agreement (the “Warrant Agreement”) and for purposes of complying with Nasdaq listing rule 5635(d) upon exercise of the underlying warrants, (i) the issuance of the shares of common stock of the Company issuable upon exercise of the warrants (the “Warrant Shares”), including the issuance of all of the Warrant Shares in excess of 19.99% of the issued and outstanding Common Stock on April 22, 2026, and (ii) the aggregate exercise price of $0.00001 per Warrant Share (the “Exercise Price”) at which the warrants may be converted, the “Warrant Issuance Proposal”). The number of shares that voted for, against, and withheld from voting for this Warrant Issuance Proposal is summarized in the table below:

Votes For	Votes Against	Votes Abstain	Broker Non-Votes

1,742,683	107,523	4,818	0

To approve, pursuant to that certain Warrant Agreement between the Company and the Company’s financial advisor pursuant to that certain investment banking agreement., dated March 17, 2026, of the adjustment of the number of shares of common stock issuable upon the exercise of the Warrants (the “Share Adjustment Proposal”) The number of shares that voted for, against, and withheld from voting for this Share Adjustment Proposal is summarized in the table below:

Votes For	Votes Against	Votes Abstain	Broker Non-Votes

1,745,709	103,550	5,764	0

To approve voluntary adjustments to the exercise price of the Warrants pursuant to the terms of the Warrant (the “Exercise Price Adjustment Proposal”). The number of shares that voted for, against, and withheld from voting for this Exercise Price Adjustment Proposal is summarized in the table below:

Votes For	Votes Against	Votes Abstain	Broker Non-Votes

1,739,702	110,483	4,839	0

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASPIRE BIOPHARMA HOLDINGS, INC.

Dated: June 22, 2026	By:	/s/ Kraig Higginson
		Kraig Higginson
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Aspire Biopharma (ASBP) stockholders vote on June 16, 2026?

Stockholders of Aspire Biopharma Holdings, Inc. voted on multiple proposals at a Special Meeting on June 16, 2026. Each proposal received strong support, with votes for each item exceeding 1.73 million and no broker non-votes reported in the results.

What were the vote totals for the main proposal at Aspire Biopharma’s 2026 Special Meeting?

The first proposal received 1,742,683 votes for, 107,523 votes against, and 4,818 abstentions. These results indicate broad stockholder support, with no broker non-votes recorded for that proposal in the Special Meeting voting outcomes.

How many proposals passed at Aspire Biopharma’s June 2026 Special Meeting?

Three proposals were voted on at the June 16, 2026 Special Meeting, each receiving more than 1.73 million votes in favor. All three items passed with no broker non-votes, reflecting consistently supportive stockholder voting outcomes across the agenda.

Did broker non-votes affect Aspire Biopharma (ASBP) 2026 Special Meeting results?

Broker non-votes did not affect the June 16, 2026 Special Meeting results, as each proposal reported zero broker non-votes. The recorded outcomes reflect only the shares that were voted for, against, or abstained on each matter.

On which exchange are Aspire Biopharma’s common stock and warrants listed?

Aspire Biopharma’s common stock, par value $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol ASBP. Its warrants, each exercisable for one share of common stock, trade on Nasdaq under the symbol ASBPW.

Who signed the June 2026 Aspire Biopharma 8-K reporting the vote results?

The report detailing the June 16, 2026 Special Meeting results was signed on behalf of Aspire Biopharma Holdings, Inc. by Chief Executive Officer Kraig Higginson, reflecting his authorization of the disclosed stockholder voting information.

Filing Exhibits & Attachments

4 documents